相关实验视频

Updated: Jan 7, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

使用大麻治疗与代谢功能障碍相关的脂肪性肝病:朋友还是敌人? 一个回顾性分析

Ruchir Paladiya¹, Anmol Singh², Madhav Changela³

¹Department of Internal Medicine, University of Connecticut Health Center, Farmington.

Journal of clinical gastroenterology

|December 26, 2025

概括

与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的大麻使用与较少的肝脏并发症有关,但心脏病发作和中风的风险增加. 需要进一步的研究来了解这些大麻使用效应.

科学领域:

肝病学和胃肠道学
心血管医学心血管医学
公共卫生公共卫生

背景情况:

大麻使用 (CU) 在合法化后有所增加,促使对其健康影响进行调查.
现有研究表明,大麻二醇具有抗炎和抗纤维素特性,对肝病模型有益.
CU在代谢功能障碍相关的脂肪性肝病 (MASLD) 结果中的特定作用仍未得到充分探索.

研究的目的:

研究大麻使用与诊断为MASLD的住院患者的临床结果之间的关联.
分析CU对MASLD人群死亡率,肝脏特异性并发症和其他并发症的影响.

主要方法:

利用2016-2020年国家住院样本 (NIS) 数据库来识别成年MASLD患者.
根据ICD-10代码将患者分为使用大麻和不使用大麻的不同类别.
采用多变量后勤回归来评估CU对结果的影响,并对混因素进行调整.

主要成果:

在3,379,484名MASLD患者中,1.54%的人报告CU.
患有CU的患者在住院死亡率,肝硬化,失补偿性肝硬化,慢性病和肝细胞癌的几率降低.
相反,CU与心肌梗塞 (MI) 和中风的几率增加有关.

结论:

在MASLD患者中同时使用大麻与肝脏相关事件的风险较低,但心脏病和中风的风险较高相关.
目前关于CU作用的临床试验数据有限.
需要进一步的研究,以阐明这些观察到的关联的潜在机制.

关键词:

大麻大麻大麻大麻大麻大麻大麻大麻肝硬化是肝硬化的一种疾病.肝脏疾病肝脏疾病与代谢功能障碍相关的脂肪性肝病.心肌梗塞的心脏病发作一次性中风中风中风中风中风药物使用障碍药物使用障碍

更多相关视频

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...